Rispoval Rs + Pi3 Intranasal
AN: 00863/2014
Issued: March 2015
SUMMARY OF PRODUCT CHARACTERISTICS
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rispoval RS+PI3 IntraNasal
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of 2 ml:
Powder
Active substance:
-
Modified live Bovine Parainfluenza type 3 virus (PI3V), thermosensitive strain RLB103, ≥105.0 and ≤108.6 CCID50*
-
Modified live Bovine Respiratory Syncytial virus (BRSV) strain 375, ≥105.0 and ≤107.2 CCID50* *CCID50: Cell Culture Infective Dose 50%
Diluent:
-
Sodium chloride 18 mg
-
Water for injection 2 ml
Excipients:
For a full list of excipients, see section 6.1.
PHARMACEUTICAL FORM
Powder and diluent for suspension for intranasal application. Slightly coloured powder and clear colourless diluent. The reconstituted, dissolved vaccine is a pinkish suspension.
CLINICAL PARTICULARS
4.1 Target Species
Cattle
4.2 Indications for Use, Specifying the Target Species
For active immunisation of maternally derived antibody positive or negative calves from 9 days of age against BRSV and PI3V,to reduce the mean titre and duration of excretion of both viruses.
Onset of protective immunity: 5 days for BRSV and 10 days for PI3V after a single vaccination.
Duration of protective immunity: 12 weeks following a single dose.The duration of protective immunity against the PI3V fraction may be reduced in MDA positive calves vaccinated before 3 weeks of age.
4.3 Contraindications
None.
4.4 Special warnings for Cattle
None.
4.5 Special precautions for use
Special precautions for use in animals
Vaccinate only healthy animals.
Vaccinal viruses can spread from vaccinated to non-vaccinated calves and may cause a serological response, but without causing clinical signs. In laboratory experimentsbased on the data using 3 week-old animals, shedding was observed for BRSVand PI3Vup to 11 and 7 days respectively after vaccination with one dose containing the maximal virus content.
Animals should preferably be vaccinated at least 10 days before a period of stress or high infection risk like re-grouping or transport of animals, or at the start of the autumn season. To achieve optimal results, it is recommended to vaccinate all the calves within the same herd.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
None
4.6 Adverse reactions (frequency and seriousness)
Published evidence shows that on rare occasions repeated exposure to RSV may trigger hypersensitivity reactions.In colostrum-deprived animals vaccinated before 3 weeks of age with a 10x overdose of vaccine, transient temperature increase, nutritional scour, abnormal faeces and demeanour were observed.
4.7 Use during pregnancy, lactation or lay
Do not use during pregnancy/lactation.
Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
Reconstitute the vaccine by aseptically adding all the liquid to the vial containing the powder components. Shake well.
Vaccination programme:
A single dose of 2 ml of reconstituted vaccine should be given intranasally using the intranasal applicators provided to cattle from the age of 9 days. It is recommended to change applicators between animals to avoid transmitting infectious organisms.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
In colostrum-deprived animals vaccinated before 3 weeks of age with a 10x overdose of vaccine, transient temperature increase, nutritional scour, abnormal faeces and demeanour were observed.
4.11 Withdrawal Period(s)
Zero days
IMMUNOLOGICAL PROPERTIES
To stimulate active immunity against BRSVand PI3V.
ATC Vet code QI02AD07 (immunologicals for bovidae, cattle, live viral vaccines, bovine Respiratory syncytial virus + bovine Parainfluenza virus).
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Powder:
-
Buffered lactose solution
-
Gelatin solution
-
Casein hydrolysate solution
-
HALS medium
6.2 Incompatibilities
Do not mix with any other veterinary medicinal product.
6.3 Shelf-life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf-life after reconstitution according to directions: 2 hours.
6.4 Special Precautions for Storage
Store and transport refrigerated (2°C to 8°C). Do not freeze. Protect from light.
6.5 Nature and composition of immediate packaging
Cardboard box with glass vial(s) of 5 or 25 doses of powder accompanied by an equal number of vial(s) containing 10 or 50 ml liquid component. Both vials have rubber stopper and aluminium cap. Nasal applicators for vaccination are also provided.
6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products, if appropriate
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
MARKETING AUTHORISATION HOLDER
Kernfarm B.V.,
De Corridor 14D,
3621 ZB Breukelen,
The Netherlands
MARKETING AUTHORISATION NUMBER
Vm43877/4000
DATE OF FIRST AUTHORISATION
27 March 2015
DATE OF REVISION OF THE TEXT
March 2015.
Approved: 27/03/2015
Page 8 of 8